当前期刊: The Lancet Neurology Go to current issue    加入关注   
显示样式:        排序: 导出
我的关注
我的收藏
您暂时未登录!
登录
  • 更新日期:2020-01-13
  • Correction to Lancet Neurol 2019; 18: 653–65
    Lancet Neurol. (IF 28.755) Pub Date : 2020-01-03

    Wilson D, Ambler G, Lee K-J, et al. Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. Lancet Neurol 2019; 18: 653–65—In this Article, the open access license has been corrected to CC BY. This correction has been made to the online version as of Jan 3, 2020.

    更新日期:2020-01-04
  • Personalising pain control with spinal cord stimulation
    Lancet Neurol. (IF 28.755) Pub Date : 2019-12-20
    Bizhan Aarabi

    Failed back surgery syndrome (irrespective of the type of surgical intervention) is a painful disorder with a substantial affective-arousal component, rendering it hard to treat. Individuals with failed back surgery syndrome have chronic back or leg pain, or both, and this syndrome also affects their functionality, emotional wellbeing, sleep cycle, and overall wellbeing. At present, more than 20% of spinal surgeries are complicated by failed back surgery syndrome.

    更新日期:2019-12-21
  • Long-term safety and efficacy of closed-loop spinal cord stimulation to treat chronic back and leg pain (Evoke): a double-blind, randomised, controlled trial
    Lancet Neurol. (IF 28.755) Pub Date : 2019-12-20
    Nagy Mekhail; Robert M Levy; Timothy R Deer; Leonardo Kapural; Sean Li; Kasra Amirdelfan; Corey W Hunter; Steven M Rosen; Shrif J Costandi; Steven M Falowski; Abram H Burgher; Jason E Pope; Christopher A Gilmore; Farooq A Qureshi; Peter S Staats; James Scowcroft; Jonathan Carlson; Christopher K Kim; Michael I Yang; Thomas Stauss; Lawrence Poree; Dan Brounstein; Robert Gorman; Gerrit E. Gmel; Erin Hanson; Dean M. Karantonis; Abeer Khurram; Deidre Kiefer; Angela Leitner; Dave Mugan; Milan Obradovic; John Parker; Peter Single; Nicole Soliday
    更新日期:2019-12-21
  • A cornerstone initiative for progress in Parkinson's disease
    Lancet Neurol. (IF 28.755) Pub Date : 2020-01-01
    The Lancet Neurology
    更新日期:2019-12-13
  • Stroke research in 2019: towards optimising treatment and prevention
    Lancet Neurol. (IF 28.755) Pub Date : 2020-01-01
    Simiao Wu; Yajun Cheng; Bo Wu; Ming Liu

    2019 saw major advances in stroke research, such as: extension of the treatment window of thrombolysis in image-selected patients, testing of direct aspiration for thrombectomy, and evidence for early intensive blood pressure control during acute stroke, restarting antiplatelet therapy after intracerebral haemorrhage, and a polypill strategy for primary prevention of stroke.

    更新日期:2019-12-13
  • Research momentum brings hope for dementia in 2019
    Lancet Neurol. (IF 28.755) Pub Date : 2020-01-01
    Julie Schneider
    更新日期:2019-12-13
  • Traumatic brain injury in 2019: databases, biomarkers, and stratified treatment
    Lancet Neurol. (IF 28.755) Pub Date : 2020-01-01
    Junfeng Feng; Jiyao Jiang
    更新日期:2019-12-13
  • Emerging treatments for headache: advances in 2019
    Lancet Neurol. (IF 28.755) Pub Date : 2020-01-01
    Gisela M Terwindt

    Migraine is a highly prevalent neurovascular disorder and the second leading cause of disability worldwide. Cortically spreading depolarisations, which underlie migraine auras, connect to the trigeminovascular system that incites migraine headaches. The role of calcitonin gene-related peptide (CGRP) during the aura is still debated, but is certain in the activation of the trigeminovascular complex. 2019 has been an important year in establishing acute and preventive new therapies for migraine.

    更新日期:2019-12-13
  • Unravelling the heterogeneity of epilepsy for optimal individualised treatment: advances in 2019
    Lancet Neurol. (IF 28.755) Pub Date : 2020-01-01
    Page B Pennell

    One of the biggest challenges in epilepsy research is the vast heterogeneity of the disorder, including differences in causes, seizure types and severity, neurophysiological and neuroimaging characteristics, comorbidities, and the individual factors that should be considered in treatment selection. In 2019, advances have allowed this heterogeneity to be deciphered with new clinical tools to deliver safer and more personalised, effective treatments to each of the 50 million people with epilepsy worldwide.

    更新日期:2019-12-13
  • Movement disorders in 2019: from antibodies to lifestyle interventions
    Lancet Neurol. (IF 28.755) Pub Date : 2020-01-01
    Claudia Trenkwalder; Brit Mollenhauer
    更新日期:2019-12-13
  • Multiple sclerosis in 2019: predicting progression
    Lancet Neurol. (IF 28.755) Pub Date : 2020-01-01
    Alexis A Lizarraga; Bianca Weinstock-Guttman

    Although it is difficult to limit the outstanding multiple sclerosis research in 2019 to a selection of publications, the most important advances were made in the identification of sensitive biomarkers for predicting and monitoring disability progression. The use of MRI to estimate long-term disease progression in multiple sclerosis has previously yielded mixed results; however, new research using novel imaging strategies could bring new clarity.

    更新日期:2019-12-13
  • Important advances in neuromuscular research in 2019
    Lancet Neurol. (IF 28.755) Pub Date : 2020-01-01
    Vera Bril

    It is challenging to select only a handful of papers, from the many published in different research areas in neuromuscular disorders, to highlight the most important advances in 2019. The focus here is on novel treatments and advances in our understanding of pathophysiology. For example, in 2019, the first randomised, placebo-controlled study of efgartigimod, an antagonist of the neonatal Fc receptor (FcRn), was done in patients with myasthenia gravis. FcRn inhibitors block the recycling of immunoglobulins, reducing levels of circulating pathogenic antibody by about 70%. In this randomised, placebo-controlled phase 2 trial, 24 patients with generalised myasthenia gravis and acetylcholine receptor antibodies were given intravenous efgartigimod (10 mg/kg) or placebo infusions four times in 3 weeks. The results of this study showed that intravenous efgartigimod was safe, well tolerated, and effective. Nine (75%) of 12 patients treated with efgartigimod significantly improved on four efficacy scales (the quantitative myasthenia gravis score, Myasthenia Gravis-specific Activities of Daily Living scale, myasthenia gravis composite scale, and Myasthenia Gravis Quality of Life scale) as early as 7 days after the first infusion, and improved maximally 1–2 weeks after the final infusion. Reductions on these four scales were observed in most patients (about three-quarters improved substantially), although one patient dropped out at day 36 because of low efficacy and worsening of myasthenia gravis. Following the success of this study, a phase 3 trial is underway in Europe, North America, and Japan ( ). Thus, FcRn inhibitors could become effective alternatives to immunoglobulin infusions, and might be used in conjunction with terminal complement inhibitors such as eculizumab or zilucoplan, which block the formation of the membrane attack complex. Addressing two different points in the aberrant immune activity is likely to improve clinical outcomes through a synergistic effect.

    更新日期:2019-12-13
  • Living without the opioid epidemic: how far have we come?
    Lancet Neurol. (IF 28.755) Pub Date : 2020-01-01
    João Batista Santos Garcia; José Osvaldo Barbosa Neto

    Pain management suffered an important set back in the past few years, with the emergence of an opioid crisis in the USA. Between 2013 and 2017, the number of opioid-related deaths increased by 90%, jumping from about 25 000 to more than 47 000 cases. At first, this growth in opioid overdose was mostly driven by prescription of opioids for pain management, especially when they were combined with benzodiazepines. With time, however, the crisis evolved into a more complex problem, as overdoses by illicitly manufactured fentanyl or fentanyl analogues mixed together started to rise. At the same time, other high-income countries, such as Canada and Australia, began to report a similar scenario, and several countermeasures were put in place worldwide to amend the situation. The opioid prescription guidelines published during this period discouraged physicians from prescribing opioids if the risks outweighed the benefits and encouraged them to minimise the duration of treatment and the initial dosage offered to patients.

    更新日期:2019-12-13
  • Advances in sleep medicine in 2019
    Lancet Neurol. (IF 28.755) Pub Date : 2020-01-01
    Swapan Dholakia; Nancy Collop

    Remarkable research findings have led to multiple advances in sleep medicine in 2019. Among the most important improvements, we would like to highlight the approval of new medication, the passing of legislation, improvements in our understanding of the effects of obstructive sleep apnoea, and advances in our knowledge about prognosis in REM sleep behavior disorder (RBD).

    更新日期:2019-12-13
  • Neurological infections in 2019: challenges, solutions, and open questions
    Lancet Neurol. (IF 28.755) Pub Date : 2020-01-01
    Uwe Koedel; Matthias Klein; Hans Walter Pfister
    更新日期:2019-12-13
  • Emerging concepts in neuroscience research: 2019 highlights
    Lancet Neurol. (IF 28.755) Pub Date : 2020-01-01
    Patrizia Casaccia

    Oligodendrocytes are the myelin-forming cells of the adult CNS, providing insulation to neurons and facilitating saltatory conduction. The identification of oligodendrocyte progenitors as the precursors of these cells, with the ability to proliferate and differentiate in the adult brain, created a wave of excitement because of their intrinsic regenerative potential. The discovery that oligodendrocyte progenitors are highly responsive to environmental cues and able to communicate with other cell types highlighted the potential of these cells to affect the pathogenesis not only of demyelinating diseases, but also of neurodegenerative and psychiatric disorders. This brief summary highlights some of the advances that have been made in 2019 in understanding the role of oligodendroglia in neurobiology and the potential relevance for neurological disorders.

    更新日期:2019-12-13
  • Cenobamate: new hope for treatment-resistant epilepsy
    Lancet Neurol. (IF 28.755) Pub Date : 2019-11-13
    Stephan Arnold

    A third of patients with epilepsy worldwide are in need of more effective anticonvulsive drugs, since their epileptic seizures remain uncontrolled with currently available medical treatments. To date, despite that a dozen new drugs have been developed in the past 20 years, the chance of complete seizure control after failure of two anticonvulsant treatments, even in patients with newly diagnosed epilepsy, is low. In The Lancet Neurology, Gregory Krauss and colleagues report results of the second phase 2 double-blind, randomised, placebo-controlled, dose-response trial on the safety and efficacy of adjunctive cenobamate (YKP3089) for the treatment of focal epilepsy. The mechanism of action of this drug is still under investigation. Beside inhibiting excitatory sodium-channel currents, it is believed that cenobamate enhances inhibition by modulation of GABAA receptors.

    更新日期:2019-12-13
  • 更新日期:2019-12-13
  • Advancing dementia prevention through effective blood pressure control
    Lancet Neurol. (IF 28.755) Pub Date : 2019-11-06
    Ruth Peters; Craig S Anderson
    更新日期:2019-12-13
  • Increased striatal dopamine in carriers of GBA mutations: compensation or epiphenomenon?
    Lancet Neurol. (IF 28.755) Pub Date : 2019-10-30
    Nicolaas I Bohnen; Roger L Albin
    更新日期:2019-12-13
  • Epilepsy genetics and the precision medicine matrix
    Lancet Neurol. (IF 28.755) Pub Date : 2019-09-04
    Sanjay M Sisodiya

    The Personal View by Colin A Ellis and colleagues in The Lancet Neurology rightly celebrates achievements in epilepsy genetics; fundamental discoveries have deepened understanding of disease biology and firmly placed the use of genomics in the clinic. For clinicians, the question is whether these developments will benefit people with epilepsy. Progress in identifying causes of the rare, severe, early-onset epilepsies, which tend to be resistant to available treatments, has fired enthusiasm for genetics-driven precision medicine, with a few impressive achievements. However, the overall picture regarding the role of precision medicine in the epilepsies is complicated.

    更新日期:2019-12-13
  • Preclinical Alzheimer's disease: a valid concept
    Lancet Neurol. (IF 28.755) Pub Date : 2020-01-01
    Clifford R Jack

    In The Lancet Neurology, Frisoni and colleagues present a thoughtful and topical Insight, but I disagree with their recommendations. They point out that, although the National Institute on Aging–Alzheimer's Association (NIA-AA) research framework recommends defining the disease biologically (by abnormal biomarkers denoting both amyloid and tau deposits) independent from symptomatic presentation, most in the lay community understand the term Alzheimer's disease to mean a progressive cognitive impairment that leads to dementia. This disparity creates a conceptual disconnect between the lay and scientific communities. The solution recommended by Frisoni and colleagues is that the term Alzheimer's disease be reserved for symptomatic individuals.

    更新日期:2019-12-13
  • Neuromyelitis optica in patients with increased interferon alpha concentrations
    Lancet Neurol. (IF 28.755) Pub Date : 2020-01-01
    Jac Williams; Sarah McGlasson; Sarosh Irani; Darragh Duffy; Yanick Crow; David Hunt; Murray Katy; Wilson Robert; Jackson Andrew P; Jury Alexa; Rodero Mathieu; Bondet Vincent; Jacob Anu; Hamid Shahd; Cordeiro Nuno; Dolezal Ondrej; Statham Patrick; Wiseman Stewart; Wardlaw Joanna; Hertel Christina; Hayday Adrian
    更新日期:2019-12-13
  • Correction to Lancet Neurol 2019; 18: 1103–11
    Lancet Neurol. (IF 28.755) Pub Date : 2020-01-01

    van der Ende EL, Meeter LH, Poos JM, et al. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol 2019; 18: 1103–11—In the affiliations of this Article, “IRCCS di Dio Fatebenefratelli, Brescia, Italy” has been corrected to “IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy”. This correction has been made to the online version as of Dec 11, 2019.

    更新日期:2019-12-13
  • Correction to Lancet Neurol 2020; 19: 23–24
    Lancet Neurol. (IF 28.755) Pub Date : 2020-01-01

    Arnold S. Cenobamate: new hope for treatment-resistant epilepsy. Lancet Neurol 2020; 19: 23–24—In this comment, the last line of paragraph two should read “patients with treatment-resistant epilepsy”. This correction has been made to the online version as of Dec 11, 2019, and will be made to the printed version.

    更新日期:2019-12-13
  • Aaron Gitler: yeast, proteins, and pioneering brain research
    Lancet Neurol. (IF 28.755) Pub Date : 2019-09-03
    Jules Morgan
    更新日期:2019-12-13
  • Rural origins of warfarin
    Lancet Neurol. (IF 28.755) Pub Date : 2020-01-01
    Taha Nisar; Harry Sutherland-Foggio; Walter Husar

    Warfarin might be the most commonly used oral anticoagulant. It was first used as a rodenticide in the 1940s, but found wide acceptance for medical use after the discovery of vitamin K as an antagonist of its action. The characterisation of the anticoagulant properties of warfarin resulted from years of research by Karl Link, at the University of Wisconsin in Madison, USA, and his students Harold Campbell and Mark Stahmann. Their experiments first led to the isolation of dicoumarol and then to the development of warfarin, a more potent anticoagulant than dicoumarol.

    更新日期:2019-12-13
  • Rickie Patani
    Lancet Neurol. (IF 28.755) Pub Date : 2020-01-01
    更新日期:2019-12-13
  • Sight reveals itself
    Lancet Neurol. (IF 28.755) Pub Date : 2019-10-11
    Robert Stirrups
    更新日期:2019-12-13
  • Rewiring public understanding of neurological disorders
    Lancet Neurol. (IF 28.755) Pub Date : 2018-11-20
    Ashley Cooper
    更新日期:2019-12-13
  • After the Gold Rush
    Lancet Neurol. (IF 28.755) Pub Date : 2019-02-14
    Robert Stirrups
    更新日期:2019-12-13
  • Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial
    Lancet Neurol. (IF 28.755) Pub Date : 2019-11-13
    Gregory L Krauss; Pavel Klein; Christian Brandt; Sang Kun Lee; Ivan Milanov; Maja Milovanovic; Bernhard J Steinhoff; Marc Kamin
    更新日期:2019-12-13
  • A support programme for secondary prevention in patients with transient ischaemic attack and minor stroke (INSPiRE-TMS): an open-label, randomised controlled trial
    Lancet Neurol. (IF 28.755) Pub Date : 2019-11-07
    Michael Ahmadi; Inga Laumeier; Thomas Ihl; Maureen Steinicke; Caroline Ferse; Matthias Endres; Armin Grau; Sidsel Hastrup; Holger Poppert; Frederick Palm; Martin Schoene; Christian L Seifert; Farid I Kandil; Joachim E Weber; Paul von Weitzel-Mudersbach; Martin L J Wimmer; Ale Algra; Pierre Amarenco; Jacoba P Greving; Otto Busse; Friedrich Köhler; Peter Marx; Heinrich J Audebert
    更新日期:2019-12-13
  • Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies
    Lancet Neurol. (IF 28.755) Pub Date : 2019-11-06
    Jie Ding; Kendra L Davis-Plourde; Sanaz Sedaghat; Phillip J Tully; Wanmei Wang; Caroline Phillips; Matthew P Pase; Jayandra J Himali; B Gwen Windham; Michael Griswold; Rebecca Gottesman; Thomas H Mosley; Lon White; Vilmundur Guðnason; Stéphanie Debette; Alexa S Beiser; Sudha Seshadri; M Arfan Ikram; Osorio Meirelles; Christophe Tzourio; Lenore J Launer
    更新日期:2019-12-13
  • Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study
    Lancet Neurol. (IF 28.755) Pub Date : 2019-10-30
    Tanya Simuni; Liz Uribe; Hyunkeun Ryan Cho; Chelsea Caspell-Garcia; Christopher S Coffey; Andrew Siderowf; John Q Trojanowski; Leslie M Shaw; John Seibyl; Andrew Singleton; Arthur W Toga; Doug Galasko; Tatiana Foroud; Duygu Tosun; Kathleen Poston; Daniel Weintraub; Brit Mollenhauer; Caroline M Tanner; Karl Kieburtz; Lana M Chahine; Alyssa Reimer; Samantha J Hutten; Susan Bressman; Kenneth Marek; Vanessa Arnedo; Adrienne Clark; Mark Fraiser; Catherine Kopil; Sohini Chowdhury; Todd Sherer; Nichole Daegele; Cynthia Casaceli; Ray Dorsey; Renee Wilson; Sugi Mahes; Christina Salerno; Karen Crawford; Paola Casalin; Giulia Malferrari; Mali Gani Weisz; Avi Orr-Urtreger; Thomas Montine; Chris Baglieri; Amanda Christini; David Russell; Nabila Dahodwala; Nir Giladi; Stewart Factor; Penelope Hogarth; David Standaert; Robert Hauser; Joseph Jankovic; Marie Saint-Hilaire; Irene Richard; David Shprecher; Hubert Fernandez; Katrina Brockmann; Liana Rosenthal; Paolo Barone; Alberto Espay; Dominic Rowe; Karen Marder; Anthony Santiago; Shu-Ching Hu; Stuart Isaacson; Jean-Christophe Corvol; Javiar Ruiz Martinez; Eduardo Tolosa; Yen Tai; Marios Politis; Debra Smejdir; Linda Rees; Karen Williams; Farah Kausar; Karen Williams; Whitney Richardson; Diana Willeke; Shawnees Peacock; Barbara Sommerfeld; Alison Freed; Katrina Wakeman; Courtney Blair; Stephanie Guthrie; Leigh Harrell; Christine Hunter; Cathi-Ann Thomas; Raymond James; Grace Zimmerman; Victoria Brown; Jennifer Mule; Ella Hilt; Kori Ribb; Susan Ainscough; Misty Wethington; Madelaine Ranola; Helen Mejia Santana; Juliana Moreno; Deborah Raymond; Krista Speketer; Lisbeth Carvajal; Stephanie Carvalo; Ioana Croitoru; Alicia Garrido; Laura Marie Payne; Veena Viswanth; Lawrence Severt; Maurizio Facheris; Holly Soares; Mark A. Mintun; Jesse Cedarbaum; Peggy Taylor; Kevin Biglan; Emily Vandenbroucke; Zulfiqar Haider Sheikh; Baris Bingol; Tanya Fischer; Pablo Sardi; Remi Forrat; Alastair Reith; Jan Egebjerg; Gabrielle Ahlberg Hillert; Barbara Saba; Chris Min; Robert Umek; Joe Mather; Susan De Santi; Anke Post; Frank Boess; Kirsten Taylor; Igor Grachev; Andreja Avbersek; Pierandrea Muglia; Kaplana Merchant; Johannes Tauscher
    更新日期:2019-12-13
  • Dementia in China: epidemiology, clinical management, and research advances
    Lancet Neurol. (IF 28.755) Pub Date : 2019-09-04
    Longfei Jia; Meina Quan; Yue Fu; Tan Zhao; Yan Li; Cuibai Wei; Yi Tang; Qi Qin; Fen Wang; Yuchen Qiao; Shengliang Shi; Yan-Jiang Wang; Yifeng Du; Jiewen Zhang; Junjian Zhang; Benyan Luo; Qiumin Qu; Chunkui Zhou; Serge Gauthier; Jianping Jia
    更新日期:2019-12-13
  • Epilepsy genetics: clinical impacts and biological insights
    Lancet Neurol. (IF 28.755) Pub Date : 2019-09-04
    Colin A Ellis; Slavé Petrovski; Samuel F Berkovic
    更新日期:2019-12-13
  • BEST evidence on mechanical thrombectomy for patients with vertebrobasilar occlusion
    Lancet Neurol. (IF 28.755) Pub Date : 2019-12-09
    Wouter J Schonewille

    Posterior circulation strokes account for about 20% of all ischaemic strokes, of which an estimated 15% are caused by large vessel vertebrobasilar occlusion. Basilar artery occlusion (BAO) is the most severe cause of ischaemic stroke, with outcomes much worse than those from anterior circulation occlusion. By contrast with evidence from multiple randomised controlled trials of the efficacy of endovascular treatment in acute ischaemic stroke due to anterior circulation occlusion, convincing evidence of efficacy of endovascular treatment in large vessel vertebrobasilar occlusion is still needed. , 

    更新日期:2019-12-11
  • Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST): an open-label, randomised controlled trial
    Lancet Neurol. (IF 28.755) Pub Date : 2019-12-09
    Xinfeng Liu, Qiliang Dai, Ruidong Ye, Wenjie Zi, Yuxiu Liu, Huaiming Wang, Wusheng Zhu, Minmin Ma, Qin Yin, Min Li, Xinying Fan, Wen Sun, Yunfei Han, Qiushi Lv, Rui Liu, Dong Yang, Zhonghua Shi, Dequan Zheng, Xiaorong Deng, Yue Wan, Zhen Wang, Yu Geng, Xingyu Chen, Zhiming Zhou, Geng Liao, Ping Jin, Yumin Liu, Xintong Liu, Meng Zhang, Feng Zhou, Hongchao Shi, Yunfeng Zhang, Fuqiang Guo, Congguo Yin, Guozhong Niu, Mei Zhang, Xueli Cai, Qiyi Zhu, Zhonglun Chen, Yingchun Liang, Bing Li, Min Lin, Wei Wang, Haowen Xu, Xinmin Fu, Wenhua Liu, Xiguang Tian, Zili Gong, Haicun Shi, Chuanming Wang, Penghua Lv, Zhonghai Tao, Liangfu Zhu, Shiquan Yang, Wei Hu, Pingzhou Jiang, David S Liebeskind, Vitor M Pereira, Thomas Leung, Bernard Yan, Stephen Davis, Gelin Xu, Raul G Nogueira, Xinfeng Liu, Gelin Xu, Wusheng Zhu, Minmin Ma, Yunyun Xiong, Wenjie Zi, Qiliang Dai, Huaiming Wang, Ruidong Ye, Yuxiu Liu, Zhonghua Shi, Dequan Zheng, Xiaorong Deng, Yue Wan, Zhen Wang, Yu Geng, Zongjie Shi, Weihong Zheng, Xingyu Chen, Zhiming Zhou, Xianjun Huang, Geng Liao, Ping Jin, Yong Liu, Yumin Liu, Huagang Li, Xintong Liu, Meng Zhang, Feng Zhou, Hongchao Shi, Kaifu Ke, Yunfeng Zhang, Fuqiang Guo, Shu Yang, Congguo Yin, Guozhong Niu, Mei Zhang, Xueli Cai, Qiyi Zhu, Zhonglun Chen, Yingchun Liang, Bing Li, Min Lin, Hang Lin, Wei Wang, Haowen Xu, Xinmin Fu, Wei Dan, Wenhua Liu, Xiguang Tian, Lin Chen, Zili Gong, Haicun Shi, Chuanming Wang, Penghua Lv, Zhonghai Tao, Liangqun Rong, Liangfu Zhu, Shuiping Wang, Shiquan Yang, Wei Hu, Pingzhou Jiang, Jin Fan, Chengming Xing, Haifeng Li, Weiming Yang, Changqing Wang, Yong Zhang, Penghua Lv, Xiaobo Li, Vitor Pereira, Bernard Yan, David Liebeskind, Thomas Leung, Stephen Davis, Raul Nogueira
    更新日期:2019-12-11
  • New routes of dopaminergic drug delivery in patients with Parkinson's disease
    Lancet Neurol. (IF 28.755) Pub Date : 2019-12-06
    Angelo Antonini

    Motor fluctuations represent a therapeutic challenge in the management of Parkinson's disease. They occur as a consequence of a combination of factors, including chronic pulsatile oral levodopa treatment, progressive loss of nigrostriatal nerve terminals, and reduced endogenous dopamine storage and release capacity. As mobility becomes progressively dependent on peripheral levodopa bioavailability, physicians need to adjust medications to preserve functionality and independence. However, fluctuations are common and can manifest with both motor and non-motor symptoms, such as depression, anxiety, or pain, making their identification in clinical practice complex. Moreover, attempts to extend the effect of levodopa are limited by delayed or erratic gastric emptying, or hampered by poor tolerability. So far, extended-release levodopa formulations have failed to provide a stable levodopa concentration and a reduced pulsatile stimulation of dopamine receptors. Therefore, research has moved to identify different routes of delivering levodopa and other dopaminergic agents.

    更新日期:2019-12-07
  • Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study
    Lancet Neurol. (IF 28.755) Pub Date : 2019-12-06
    C Warren Olanow, Stewart A Factor, Alberto J Espay, Robert A Hauser, Holly A Shill, Stuart Isaacson, Rajesh Pahwa, Mika Leinonen, Parul Bhargava, Ken Sciarappa, Bradford Navia, David Blum, xx xx
    更新日期:2019-12-07
  • The global burden of neurological disorders: translating evidence into policy
    Lancet Neurol. (IF 28.755) Pub Date : 2019-12-05
    Valery L Feigin, Theo Vos, Emma Nichols, Mayowa O Owolabi, William M Carroll, Martin Dichgans, Günther Deuschl, Priya Parmar, Michael Brainin, Christopher Murray
    更新日期:2019-12-06
  • The growing burden of neurological disorders in low-income and middle-income countries: priorities for policy making
    Lancet Neurol. (IF 28.755) Pub Date : 2019-12-05
    Andrea S Winkler

    Neurological disorders are the largest contributor to the global burden of disease in terms of morbidity, as measured with disability-adjusted life years, and the second largest contributor to mortality. If neurological disorders are included that have so far not been accounted for in the Global Burden of Diseases, Injuries, and Risk Factors (GBD) study, such as cerebral malaria, then the proportion of people with neurological diseases becomes even larger, especially in low-income and middle-income countries (LMICs). The Policy View in The Lancet Neurology by Feigin and colleagues, which sets out priorities and recommendations to tackle the growing burden of neurological disorders using GBD data, is therefore a welcome and timely call for action.

    更新日期:2019-12-06
  • A resurrection of aducanumab for Alzheimer's disease
    Lancet Neurol. (IF 28.755) Pub Date : 2019-12-04
    Lon Schneider
    更新日期:2019-12-04
  • International view on genetic frontotemporal dementia
    Lancet Neurol. (IF 28.755) Pub Date : 2019-12-03
    Eline Wauters, Christine Van Broeckhoven

    Frontotemporal dementia is a subtype of neurodegenerative dementia, characterised by progressive changes in behaviour and personality or language difficulties. Frontotemporal dementia has a strong genetic component, and microtubule-associated protein tau (MAPT), progranulin (GRN), and chromosome 9 open reading frame 72 (C9orf72) are the most common mutated genes. Patients with this condition show heterogeneity in clinical presentation and a wide variability in age at symptom onset, age at death, and disease duration.,  ,  This heterogeneity represents a challenge for clinical diagnostics, genetic counselling, and therapy development and evaluation.

    更新日期:2019-12-04
  • Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study
    Lancet Neurol. (IF 28.755) Pub Date : 2019-12-03
    Katrina M Moore, Jennifer Nicholas, Murray Grossman, Corey T McMillan, David J Irwin, Lauren Massimo, Vivianna M Van Deerlin, Jason D Warren, Nick C Fox, Martin N Rossor, Simon Mead, Martina Bocchetta, Bradley F Boeve, David S Knopman, Neill R Graff-Radford, Leah K Forsberg, Rosa Rademakers, Zbigniew K Wszolek, John C van Swieten, Lize C Jiskoot, Lieke H Meeter, Elise GP Dopper, Janne M Papma, Julie S Snowden, Jennifer Saxon, Matthew Jones, Stuart Pickering-Brown, Isabelle Le Ber, Agnès Camuzat, Alexis Brice, Paola Caroppo, Roberta Ghidoni, Michela Pievani, Luisa Benussi, Giuliano Binetti, Bradford C Dickerson, Diane Lucente, Samantha Krivensky, Caroline Graff, Linn Öijerstedt, Marie Fallström, Håkan Thonberg, Nupur Ghoshal, John C Morris, Barbara Borroni, Alberto Benussi, Alessandro Padovani, Daniela Galimberti, Elio Scarpini, Giorgio G Fumagalli, Ian R Mackenzie, Ging-Yuek R Hsiung, Pheth Sengdy, Adam L Boxer, Howie Rosen, Joanne B Taylor, Matthis Synofzik, Carlo Wilke, Patricia Sulzer, John R Hodges, Glenda Halliday, John Kwok, Raquel Sanchez-Valle, Albert Lladó, Sergi Borrego-Ecija, Isabel Santana, Maria Rosário Almeida, Miguel Tábuas-Pereira, Fermin Moreno, Myriam Barandiaran, Begoña Indakoetxea, Johannes Levin, Adrian Danek, James B Rowe, Thomas E Cope, Markus Otto, Sarah Anderl-Straub, Alexandre de Mendonça, Carolina Maruta, Mario Masellis, Sandra E Black, Philippe Couratier, Geraldine Lautrette, Edward D Huey, Sandro Sorbi, Benedetta Nacmias, Robert Laforce, Marie-Pier L Tremblay, Rik Vandenberghe, Philip Van Damme, Emily J Rogalski, Sandra Weintraub, Alexander Gerhard, Chiadi U Onyike, Simon Ducharme, Sokratis G Papageorgiou, Adeline Su Lyn, Amy Brodtmann, Elizabeth Finger, Rita Guerreiro, Jose Bras, Jonathan D Rohrer, Carolin Heller, Rhian S Convery, Ione OC Woollacott, Rachelle M Shafei, Jonathan Graff-Radford, David T Jones, Christina M Dheel, Rodolfo Savica, Maria I Lapid, Matt Baker, Julie A Fields, Ralitza Gavrilova, Kimiko Domoto-Reilly, Jackie M Poos, Emma L Van der Ende, Jessica L Panman, Laura Donker Kaat, Harro Seelaar, Anna Richardson, Giovanni Frisoni, Anna Mega, Silvia Fostinelli, Huei-Hsin Chiang, Antonella Alberici, Andrea Arighi, Chiara Fenoglio, Hilary Heuer, Bruce Miller, Anna Karydas, Jamie Fong, Maria João Leitão, Beatriz Santiago, Diana Duro, Carlos Ferreira, Alazne Gabilondo, Maria De Arriba, Mikel Tainta, Miren Zulaica, Catarina Ferreira, Elisa Semler, Albert Ludolph, Bernhard Landwehrmeyer, Alexander E Volk, Gabriel Miltenberger, Ana Verdelho, Sónia Afonso, Maria Carmela Tartaglia, Morris Freedman, Ekaterina Rogaeva, Camilla Ferrari, Irene Piaceri, Valentina Bessi, Gemma Lombardi, Frédéric St-Onge, Marie-Claire Doré, Rose Bruffaerts, Mathieu Vandenbulcke, Jan Van den Stock, M Marsel Mesulam, Eileen Bigio, Christos Koros, John Papatriantafyllou, Christos Kroupis, Leonidas Stefanis, Christien Shoesmith, Erik Robertson, Giovanni Coppola, Eliana Marisa Da Silva Ramos, Daniel Geschwind
    更新日期:2019-12-04
  • Essential tremor-plus: a temporary label
    Lancet Neurol. (IF 28.755) Pub Date : 2019-11-22
    Marie Vidailhet

    In the 2018 consensus statement by the Movement Disorder Society on the classification of tremors, the definition of essential tremor (ET) was narrowed to bilateral upper limbs action tremor with the arbitrary cutoff of at least 3 years' duration. Besides ET, an essential tremor-plus (ET-plus) category was created, with additional neurological signs of uncertain clinical significance, including rest tremor, mild cognitive signs, mild neuropathy, mild ataxia, or questionable dystonic postures with no clear boundaries.

    更新日期:2019-11-26
  • Essential tremor-plus: a controversial new concept
    Lancet Neurol. (IF 28.755) Pub Date : 2019-11-22
    Elan D Louis, Martin Bares, Julian Benito-Leon, Stanley Fahn, Steven J Frucht, Joseph Jankovic, William G Ondo, Pramod K Pal, Eng-King Tan

    In addition to redefining essential tremor (ET), the 2018 consensus statement of the Movement Disorder Society on tremor coined a new term: essential tremor-plus (ET-plus). This term is uncertainly defined as tremor with the characteristics of ET, with additional neurological signs of uncertain clinical significance. If ET-plus had been defined on the basis of a difference in underlying pathology or an appreciable difference in prognosis, it would have a valid, scientific rationale, as does the term Parkinson-plus. However, there is no such evidence, so the basis for the term is questionable. In fact, ET-plus might only represent a state condition (ie, patients with ET might develop these additional clinical features when the disease is at a more advanced stage). We caution against coining new terms that are not supported by a firm scientific basis and encourage research into the creation of essential tremor subsets that are defined with respect to differences in underlying causes or pathophysiology.

    更新日期:2019-11-26
  • A sleep disorder more than three decades later
    Lancet Neurol. (IF 28.755) Pub Date : 2019-11-20
    Zenobia Zaiwalla
    更新日期:2019-11-21
  • 更新日期:2019-11-21
  • The gut microbiome in neurological disorders
    Lancet Neurol. (IF 28.755) Pub Date : 2019-11-18
    John F Cryan, Kenneth J O'Riordan, Kiran Sandhu, Veronica Peterson, Timothy G Dinan
    更新日期:2019-11-20
  • The pain of a migraine
    Lancet Neurol. (IF 28.755) Pub Date : 2019-07-12
    Jules Morgan
    更新日期:2019-11-18
  • Pseudomedicine for sports concussions in the USA
    Lancet Neurol. (IF 28.755) Pub Date : 2019-07-03
    Kathleen E Bachynski, James M Smoliga
    更新日期:2019-11-18
  • Smart homes for the future of dementia care
    Lancet Neurol. (IF 28.755) Pub Date : 2019-07-02
    Jonathan Blott
    更新日期:2019-11-18
  • Our Dementia Choir hits the right notes
    Lancet Neurol. (IF 28.755) Pub Date : 2019-06-21
    Peter Ranscombe
    更新日期:2019-11-18
  • Wordsworth, Bellow, and understanding multiple sclerosis
    Lancet Neurol. (IF 28.755) Pub Date : 2019-06-14
    Anthony Feinstein
    更新日期:2019-11-18
  • The unique and specialised history of Queen Square
    Lancet Neurol. (IF 28.755) Pub Date : 2019-06-12
    Peter J Koehler
    更新日期:2019-11-18
  • 更新日期:2019-11-18
  • Creating a personal music playlist to help treat dementia
    Lancet Neurol. (IF 28.755) Pub Date : 2019-06-09
    Peter Ranscombe
    更新日期:2019-11-18
Contents have been reproduced by permission of the publishers.
导出
全部期刊列表>>
2020新春特辑
限时免费阅读临床医学内容
ACS材料视界
科学报告最新纳米科学与技术研究
清华大学化学系段昊泓
自然科研论文编辑服务
中国科学院大学楚甲祥
中国科学院微生物研究所潘国辉
中国科学院化学研究所
课题组网站
X-MOL
北京大学分子工程苏南研究院
华东师范大学分子机器及功能材料
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug